;

Editorial & Advertiser disclosure

Global Banking and Finance Review is an online platform offering news, analysis, and opinion on the latest trends, developments, and innovations in the banking and finance industry worldwide. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Home > Finance > Novartis to acquire Avidity Biosciences for about $12 billion

Finance

Novartis to acquire Avidity Biosciences for about $12 billion

Published by Global Banking and Finance Review

Posted on October 26, 2025

Featured image for article about Finance

(Reuters) -Swiss drugmaker Novartis on Sunday said it agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion in cash.

Avidity stockholders will receive $72 per share in cash, representing a premium of 46% to the company's closing on Friday.

Under the terms of agreement, Avidity will separate its early-stage precision cardiology programs into a new company called Spinco.

Novartis has been actively striking deals in 2025 as it looks to bolster its drug pipeline and drive future growth, and the Financial Times reported in August that the Swiss drugmaker had approached Avidity Biosciences for a potential takeover offer.

(Reporting by Angela Christy in Bengaluru)

More from Finance

Explore more articles in the Finance category

Reactions to European Commission proposal to reverse 2035 combustion engine ban

Italy's offshore wind push languishes, putting climate goals at risk

New Rome metro stations showcase ancient treasures after years of delays

Exclusive-California Pizza Kitchen reaches buyout deal, names new leadership

Greeks protest against low wages ahead of 2026 budget vote

AI boom seen lifting chipmaking equipment sales 9% to $126 billion in 2026

New Czech government signals tough stance on migration, EU emissions rules

Exclusive-Swiss firm Barry Callebaut eyes separating cocoa division amid price volatility, sources say

Zaporizhzhia nuclear plant running on single power line, Russia says

EU talks to fund Ukraine with Russian assets make progress, key decisions seen Thursday

Shell greenlights US Gulf waterflood project to boost oil recovery

Saudi firm Midad among frontrunners to buy Lukoil's global assets, sources say

View All Finance Posts